Rapid Structural and Functional Improvements in Following 0.19 mg Fluocinolone Acetonide (FAc) Implant in Diabetic Macular Edema Patients With Poor Visual Acuity: 12-month Audit Results From United Arab Emirates

Benha University

Status: Unknown

Conditions: Diabetic Macular Edema

Treatments: Device: 0.19 mg fluocinolone acetonide (FAc) implant

Study type: Observational

Funder types: Other

Identifiers

NCT03590587

skmc

Details and patient eligibility

About

The Health Authority - Abu Dhabi (HAAD) approved the reimbursement of the slow release FAc implant (ILUVIEN) and it is now available for the treatment of diabetic macular edema (DME) in persons who have been previously treated with a course of corticosteroids and did not have a clinically significant rise in intraocular pressure. We performed a retrospective 12-month audit to assess the efficacy and safety of the FAc implant in our clinical practice.

Full description

Twenty patients with pseudophakic lenses, treated with ILUVIEN, were investigated to evaluate functional and anatomical characteristics and outcomes (visual acuity [VA; ETDRS letters score], central macular thickness [CMT] and intraocular pressure [IOP]) at baseline, weeks 2-4 and months 3, 6 and 12 months.

Enrollment: 30 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• DME
• Pseudophakic

Exclusion criteria

• Other causes of macular edema.
• Phakic
• Know case of gaucoma

Trial design

30 participants in 1 patient group

1

Description:

patients treated with 0.19 mg fluocinolone acetonide (FAc) implant for 12 months

Treatment:

Device: 0.19 mg fluocinolone acetonide (FAc) implant

Device: 0.19 mg fluocinolone acetonide (FAc) implant